TaperCommunitytopiramate
Topiramate is an anticonvulsant used for epilepsy, migraine prevention, and off-label for mood, alcohol use disorder, and weight loss in obese patients. Cognitive side effects ("Dopamax") are common and can be substantial.
25mg, 50mg, 100mg, 200mg tablets; 15mg, 25mg sprinkle capsules
Tablets: 25mg, 50mg, 100mg, 200mg; Sprinkle capsules: 15mg, 25mg; ER capsules (Trokendi XR, Qudexy XR): 25mg-200mg
Category D (cleft lip/palate risk)
Multiple: blocks voltage-gated sodium channels, enhances GABA-A activity, antagonizes AMPA/kainate glutamate receptors, weakly inhibits carbonic anhydrase.
Slow taper, especially in seizure or migraine patients. Cognitive side effects often resolve quickly after dose reduction.
Cognitive blunting is dose-dependent and largely reversible — a fact often missed by patients told their cognitive changes were unrelated.
3-7 days
1-2 weeks
2-4 weeks
Cognitive recovery typically within 2-6 weeks of stopping
Toxicity
Cognitive impairment ("word-finding difficulty"), paresthesias, kidney stones (carbonic anhydrase inhibition), metabolic acidosis, anhidrosis with hyperthermia, weight loss, narrow-angle glaucoma (rare, acute).
Topamax (topiramate) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Neutral, high-authority entity references.
Official prescribing information and safety notices.
Primary literature cited in this taper guide.
Evidence-based deprescribing and prescribing standards.
Clinician-facing references on tapering protocols.
Long-running communities documenting withdrawal experience.
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.
Pharmacokinetics
Largely renal (~70% excreted unchanged); minor hepatic metabolism.
~15-41%
Browse our map of deprescribing-informed providers worldwide.